The new IP tribunal shows that China is accepting its responsibilities as a world leader in IP policy, says the former US Federal Circuit chief judge.
As the fourth industrial revolution gets underway, operating companies need to ensure that their IP strategies are fit for a rapidly changing technological landscape.
While disputes brought before the International Trade Commission relating to biologics and biosimilar patents are rare, there is a growing case for why rights holders in this sector should consider the commission as part of their litigation strategy.
China’s healthcare sector is booming and while the patent system has developed considerably in recent years, pharmaceutical companies should still think carefully about how to protect their rights.
As the Chinese authorities continue to promote the rapid development of the country’s IP market, they are also investing more efforts into countering various forms of patent market abuse.
With the advent of the Internet of Things, the semiconductor sector is on the brink of another step change – a group of IP executives at leading chip companies talk to us about how patent strategy is evolving.
New USPTO guidelines on subject matter eligibility have been met with praise from many patent owners but may diverge from US Supreme Court precedent.
Another lawsuit in the United States shows how litigation strategies for implementers and owners of SEPs are continuing to evolve.
The public IP company sector might have suffered of late but it is not going away just yet.
How boards of directors can better understand the leading source of a company’s value.
What the latest Federal Circuit 101 decision means for the medical diagnostics sector.
Storm clouds are gathering over the most talked about company in the telecoms sector but as we embark on a new era of mobile technology, Huawei still enjoys a number of notable advantages.
The big stories from the IAM platform in February and March.
A selection of recently reported facts and figures.